Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in mild to moderate nonproliferative diabetic retinopathy: A randomized proof-of-concept clinical trial

JAMA Ophthalmology

Volumn 132, Issue 9, 2014, Pages 1137-1142

  Scott, Ingrid U ^a,b   Jackson, Gregory R ^a,c   Quillen, David A ^a   Klein, Ronald ^d   Liao, Jason ^b   Gardner, Thomas W ^e  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c MacuLogix Inc ^*  (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DARK ADAPTATION; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; VISION; VISUAL ACUITY; AGED; DISEASE COURSE; DRUG EFFECTS; INSULIN DEPENDENT DIABETES MELLITUS; MICROGLIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERIMETRY; PHYSIOLOGY; RETINA NERVE CELL; VISUAL FIELD;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; CONTRAST SENSITIVITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MICROGLIA; MIDDLE AGED; RETINAL NEURONS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84907532734     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.1422     Document Type: Article

References (18)

1. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54(5):1559-1565.
2. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem. 2001;8(3):305-316.
3. Ryan ME, Ramamurthy NS, Golub LM. Tetracyclines inhibit protein glycation in experimental diabetes. Adv Dent Res. 1998;12(2):152-158.
4. Craig RG, Yu Z, Xu L, et al. A chemically modified tetracycline inhibits streptozotocin-induced diabetic depression of skin collagen synthesis and steady-state type I procollagen mRNA. Biochim Biophys Acta. 1998;1402(3):250-260.
5. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126(2):227-232.
6. Gaucher D, Chiappore JA, Pâques M, et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47(5):612-623.
7. Wang AL, Yu AC, Lau LT, et al. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem Int. 2005;47(1-2):152-158.
8. Federici TJ. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol Res. 2011;64(6):614-623.
9. Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT. Oralminocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53(7):3865-3874.
10. Kirkwood KL, Golub LM, Bradford PG. Non-antimicrobial and antimicrobial tetracyclines inhibit IL-6 expression in murine osteoblasts. Ann N Y Acad Sci. 1999;878:667-670.
11. Scott IU, Jackson GR, Quillen DA, et al. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2014;132(5):535-543.
12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology. 1991;98(5)(suppl):786-806.
13. Jackson GR, Scott IU, Quillen DA, Walter LE, Gardner TW. Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96(5):699-703.
14. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD; NEI-VFQ Field Test Investigators. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol. 1998;116(11):1496-1504.
15. Owsley C, McGwin G Jr, Scilley K, Kallies K. Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy. Invest Ophthalmol Vis Sci. 2006;47(2):528-535.
16. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
17. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS report No. 8. Ophthalmology. 1981;88(7):583-600.
18. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmology. 1978;85(1):82-106.